嘉应制药(002198) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 reached ¥94,498,587.86, representing a year-on-year increase of 19.01%[5] - Net profit attributable to shareholders for Q3 2025 was ¥1,711,738.22, a significant increase of 161.26% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥1,353,870.99, up 144.51% year-on-year[5] - Basic earnings per share for Q3 2025 were ¥0.0034, reflecting a 161.32% increase from the previous year[5] - The total profit for Q3 2025 was ¥25,741,005.94, marking a 435.45% increase year-on-year, primarily due to increased operating income[9] - Net profit for the period was ¥21,794,297.70, significantly higher than ¥2,873,345.95 in the previous period, marking an increase of 658.73%[20] - The total comprehensive income for the period reached ¥20,783,297.70, a significant increase from ¥2,873,345.95 in the previous period[21] - Basic and diluted earnings per share both improved to ¥0.0429, compared to ¥0.0057 in the prior period[21] Assets and Liabilities - Total assets at the end of Q3 2025 amounted to ¥774,726,400.45, a decrease of 7.64% from the end of the previous year[5] - The company's total assets decreased to ¥774,726,400.45 from ¥838,820,451.71, a decline of 7.66%[18] - Current assets totaled ¥466,108,240.34, down 15.77% from ¥553,758,364.26 at the beginning of the period[17] - Non-current assets increased to ¥308,618,160.11, up from ¥285,062,087.45, representing an increase of 8.25%[17] - The company's total liabilities decreased to ¥65,718,005.22 from ¥80,599,696.61, a reduction of 18.43%[18] - The equity attributable to shareholders decreased to ¥709,008,395.23 from ¥758,220,755.10, a decline of 6.48%[18] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥71,227,192.33, a decline of 489.39% compared to the previous year[5] - The net cash flow from operating activities for the first nine months of 2025 was -71,227,192.33 RMB, a decrease of 489.39% compared to 18,291,801.37 RMB in the same period of 2024[10] - Cash received from other operating activities increased by 1235.39% to 52,537,639.24 RMB, primarily due to the recovery of inter-company loans from a related party[10] - The cash outflow for investing activities was -64,578,523.83 RMB, representing a 41.32% increase from -45,695,886.29 RMB in the previous year, mainly due to increased long-term asset investments[10] - The cash and cash equivalents at the end of the period decreased by 36.45% to 127,892,923.27 RMB, attributed to stock repurchases and investment expenditures[10] - Cash inflow from operating activities totaled ¥332,072,556.68, slightly up from ¥322,546,142.28 year-over-year[22] - The net cash flow from investing activities was -¥64,578,523.83, compared to a positive ¥90,493,577.13 last year[22] - The net cash flow from financing activities was -¥69,995,657.57, worsening from -¥25,401,080.43 in the previous period[22] - The ending cash and cash equivalents balance decreased to ¥127,892,923.27 from ¥216,891,217.73 year-over-year[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,483, with no preferred shareholders[11] - The largest shareholder, Dongfang Securities Co., Ltd., holds 10.28% of the shares, amounting to 52,148,000 shares[12] - The second-largest shareholder, Yangtianhe Pharmacy Co., Ltd., owns 7.00% of the shares, totaling 35,525,690 shares[12] Administrative and Regulatory Matters - The company received an administrative penalty notice from the China Securities Regulatory Commission, but it does not expect significant impacts on its operations[14] - The company did not undergo an audit for the third quarter financial report[23] - The financial report for the third quarter was released on October 29, 2025[24] Research and Development - Research and development expenses for the period were ¥7,167,677.83, compared to ¥5,583,739.76 in the previous period, indicating an increase of 28.48%[19] Other Financial Metrics - Accounts receivable increased by 76.25% to ¥135,696,791.67, attributed to relaxed credit policies and extended payment cycles for some customers[8] - Prepayments surged by 4723.06% to ¥78,816,564.06, mainly due to investments in drug approvals and R&D[8] - The company reported a 443.95% increase in operating profit, reaching ¥25,640,486.44, driven by higher revenue and reduced expenses[9] - Total operating revenue for the period reached ¥293,436,251.95, an increase of 13.03% compared to ¥259,604,624.04 in the previous period[19] - Total operating costs amounted to ¥266,450,162.51, up from ¥256,532,928.46, reflecting a growth of 3.56%[19] - The company reported a financial asset impairment loss of ¥1,296,086.72, compared to a loss of ¥353,872.07 in the previous period[20]